TEK and colorectal carcinoma: Based on the high impact of the Ang/Tie2 axis and TEM populations on anti-angiogenic therapy response, we hypothesize that monitoring changes in TEM blood counts along with Ang2 levels before and during anti-angiogenic therapy across large cohorts of CRC patients at various disease stages might yield a valuable predictive biomarker for treatment response and overall benefit.